MeiraGTx to Participate in Upcoming Investor Conferences

Rhea-AI Summary

MeiraGTx Holdings (NASDAQ:MGTX) announced participation in two upcoming investor conferences. CEO Alexandria Forbes will engage in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on September 14, 2022, at 3:30 p.m. ET. She will also participate in a panel on Gene Regulation and a subsequent fireside chat at Chardan's 6th Annual Genetic Medicines Conference on October 4, 2022. Live webcasts and replays of the discussions will be available on the company's investor website.

LONDON and NEW YORK, Sept. 08, 2022 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., President and Chief Executive Officer, will participate in the following investor conferences:

• Morgan Stanley 20th Annual Global Healthcare Conference
  

Fireside Chat: Wednesday, September 14, 2022, at 3:30 p.m. ET

• Chardan's 6th Annual Genetic Medicines Conference
  

Panel Discussion: “Gene Regulation”, Tuesday, October 4, 2022, at 9:30 a.m. ET

Fireside Chat: Tuesday, October 4, 2022, at 10:30 a.m. ET

A live webcast of the fireside chats will be available on the Investors page of the Company’s website at www.investors.meiragtx.com. Replays will be available for approximately 30 days following the presentation dates.

About MeiraGTx

MeiraGTx (Nasdaq: MGTX) is a vertically integrated, clinical stage gene therapy company with six programs in clinical development and a broad pipeline of preclinical and research programs. MeiraGTx has core capabilities in viral vector design and optimization and gene therapy manufacturing, and a transformative gene regulation platform technology which allows tight, dose responsive control of gene expression by oral small molecules with dynamic range that can exceed 5000-fold. Led by an experienced management team, MeiraGTx has taken a portfolio approach by licensing, acquiring, and developing technologies that give depth across both product candidates and indications. MeiraGTx’s initial focus is on three distinct areas of unmet medical need: ocular, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases and severe forms of xerostomia. Though initially focusing on the eye, central nervous system, and salivary gland, MeiraGTx plans to expand its focus to develop additional gene therapy treatments for patients suffering from a range of serious diseases.

For more information, please visit www.meiragtx.com.

Contacts

Investors:
MeiraGTx
Investors@meiragtx.com

Media:
Jason Braco, Ph.D.
LifeSci Communications
jbraco@lifescicomms.com

FAQ

What are the dates of MeiraGTx's upcoming investor conferences?

MeiraGTx will participate in the Morgan Stanley 20th Annual Global Healthcare Conference on September 14, 2022, and Chardan's 6th Annual Genetic Medicines Conference on October 4, 2022.

When will the fireside chat at Morgan Stanley's conference occur?

The fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference will take place on September 14, 2022, at 3:30 p.m. ET.

What topics will be covered at the Chardan conference?

At Chardan's 6th Annual Genetic Medicines Conference, MeiraGTx will discuss gene regulation during a panel and hold a fireside chat.

Where can I access the live webcast of MeiraGTx's presentations?

The live webcast of MeiraGTx's presentations will be available on the Investors page of their website.

How long will the replays of the conferences be available?

Replays of the conferences will be available for approximately 30 days following the presentation dates.